NasdaqGM:OCULPharmaceuticals
What Ocular Therapeutix (OCUL)'s SOL-X Long-Term AXPAXLI Extension Study Means For Shareholders
Ocular Therapeutix recently enrolled the first patient in its SOL-X long-term extension trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration, a 36‑month open-label study designed to assess long-term safety, efficacy, and disease-modifying potential following completion of the SOL-1 or SOL-R trials.
This extension study is intended to test whether earlier and sustained AXPAXLI therapy can reduce fibrosis, macular atrophy, and treatment burden compared with pulsatile anti-VEGF...